BROOKS LABORATORIES
|
BROOKS LABORATORIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 8.35 | -3.38 | -7.46 | -8.46 | -4.57 |
| CEPS(Rs) | 8.89 | -2.84 | -6.79 | -9.63 | -4.80 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 41.64 | 33.30 | 24.99 | 29.94 | 35.42 |
| Tax Rate(%) | - | -1.79 | -0.13 | 19.09 | 19.19 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 8.23 | 1.62 | 3.86 | -41.80 | -15.63 |
| EBIT Margin(%) | 29.65 | -10.61 | -23.55 | -57.25 | -22.81 |
| Pre Tax Margin(%) | 28.67 | -11.86 | -24.62 | -60.71 | -26.21 |
| PAT Margin (%) | 28.67 | -12.07 | -24.65 | -49.12 | -21.18 |
| Cash Profit Margin (%) | 30.53 | -10.13 | -22.42 | -38.00 | -13.12 |
| Performance Ratios | |||||
| ROA(%) | 18.08 | -9.31 | -19.59 | -20.41 | -10.83 |
| ROE(%) | 22.27 | -12.18 | -28.08 | -38.46 | -23.18 |
| ROCE(%) | 21.72 | -10.03 | -24.92 | -37.83 | -18.72 |
| Asset Turnover(x) | 0.63 | 0.77 | 0.79 | 0.42 | 0.51 |
| Sales/Fixed Asset(x) | 3.35 | 3.41 | 3.45 | 0.76 | 0.66 |
| Working Capital/Sales(x) | 5.50 | 7.48 | 9.93 | -11.67 | 7.41 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.30 | 0.29 | 0.29 | 1.31 | 1.51 |
| Receivable days | 76.86 | 80.26 | 66.75 | 87.83 | 62.77 |
| Inventory Days | 43.05 | 41.59 | 48.02 | 112.11 | 102.32 |
| Payable days | 89.64 | 98.11 | 125.11 | 185.27 | 171.35 |
| Valuation Parameters | |||||
| PER(x) | 4.49 | - | - | - | - |
| PCE(x) | 4.22 | -37.94 | -13.67 | -6.44 | -14.99 |
| Price/Book(x) | 0.90 | 3.24 | 3.71 | 2.09 | 2.05 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 1.28 | 3.90 | 3.12 | 2.52 | 2.19 |
| EV/Core EBITDA(x) | 13.39 | 55.34 | 59.41 | -6.08 | -14.85 |
| EV/EBIT(x) | 4.33 | -36.77 | -13.24 | -4.40 | -9.60 |
| EV/CE(x) | 0.85 | 3.09 | 3.51 | 2.00 | 1.03 |
| M Cap / Sales | 1.29 | 3.84 | 3.06 | 2.45 | 1.97 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 3.85 | 3.86 | 25.76 | -30.69 | 18.04 |
| Core EBITDA Growth(%) | 41.36 | 39.52 | 115.92 | -94.85 | -1,170.52 |
| EBIT Growth(%) | 390.06 | 53.19 | 48.27 | -73.97 | -252.86 |
| PAT Growth(%) | 346.65 | 49.13 | 36.90 | -60.76 | 0.33 |
| EPS Growth(%) | 346.65 | 54.67 | 11.74 | -85.05 | 41.73 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.06 | 0.06 | 0.08 | 0.08 | 0.28 |
| Current Ratio(x) | 1.72 | 1.48 | 1.35 | 0.84 | 1.25 |
| Quick Ratio(x) | 1.21 | 1.08 | 0.93 | 0.49 | 0.69 |
| Interest Cover(x) | 30.43 | -8.52 | -22.16 | -16.58 | -6.72 |
| Total Debt/Mcap(x) | 0.07 | 0.02 | 0.02 | 0.04 | 0.14 |
Compare Financial Ratios of peers of BROOKS LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| BROOKS LABORATORIES | ₹185.4 Cr | 3.1% | -10.1% | -57.6% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹461,848.0 Cr | -1.4% | -1.3% | 21.5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹225,648.0 Cr | 2.7% | 16.1% | 38.6% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹184,109.0 Cr | -1.5% | -3.3% | 35.6% | Stock Analytics | |
| CIPLA | ₹117,139.0 Cr | -0.7% | 1.4% | -2% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹100,328.0 Cr | 3.9% | -1.8% | 0.4% | Stock Analytics | |
BROOKS LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| BROOKS LABORATORIES | 3.1% |
-10.1% |
-57.6% |
| SENSEX | -0.6% |
1.1% |
-3.2% |
You may also like the below Video Courses
